


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:47:37Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405438" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405438</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>scirep</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405438</article-id><article-id pub-id-type="pmcid-ver">PMC12405438.1</article-id><article-id pub-id-type="pmcaid">12405438</article-id><article-id pub-id-type="pmcaiid">12405438</article-id><article-id pub-id-type="pmid">40897757</article-id><article-id pub-id-type="doi">10.1038/s41598-025-06559-9</article-id><article-id pub-id-type="publisher-id">6559</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">Echinacea purpurea</italic> ameliorates Bleomycin-induced pulmonary fibrosis in rats through modulating NADPH oxidase-4 and endothelin-1/connective tissue growth factor/matrix metalloproteinases signalling axis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9870-5583</contrib-id><name name-style="western"><surname>Salama</surname><given-names initials="AAA">Abeer A. A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2948-5449</contrib-id><name name-style="western"><surname>Elgohary</surname><given-names initials="R">Rania</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-2761-4123</contrib-id><name name-style="western"><surname>Elwahab</surname><given-names initials="SA">Sahar Abd</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5765-350X</contrib-id><name name-style="western"><surname>Mostafa</surname><given-names initials="RE">Rasha E.</given-names></name><address><email>rashaemostafa@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05prbcv50</institution-id><institution-id institution-id-type="GRID">grid.489213.5</institution-id><institution>Pharmacology Department, Medical Research and Clinical Studies Institute, </institution><institution>National Research Centre (ID: 60014618), </institution></institution-wrap>33 ELBohouth St. (former EL Tahrir St.), P.O. 12622, Dokki, Cairo Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02n85j827</institution-id><institution-id institution-id-type="GRID">grid.419725.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 8157</institution-id><institution>Narcotics, Ergogenics and Poisons Department, Medical Research and Clinical Studies Institute, </institution><institution>National Research Centre, </institution></institution-wrap>Dokki, Cairo Egypt </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03q21mh05</institution-id><institution-id institution-id-type="GRID">grid.7776.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 9286</institution-id><institution>Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, </institution><institution>Cairo University, </institution></institution-wrap>Cairo, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>32332</elocation-id><history><date date-type="received"><day>20</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="41598_2025_Article_6559.pdf"/><abstract id="Abs1"><p id="Par1">Idiopathic pulmonary fibrosis (IPF) is one of the rapidly progressing interstitial lung illnesses. Bleomycin (Bleo) is used as a chemotherapeutic agent for the treatment of lymphoma patients. The major side effects of Bleo include lung fibrosis, characterized by the accumulation of inflammatory cells. <italic toggle="yes">Echinacea purpurea</italic> (ECH) possesses immune-modulating, antiviral, antimicrobial and anti-inflammatory activities. The current study aims to evaluate the possible protective effects of ECH against Bleomycin-induced pulmonary fibrosis. Forty rats were divided into four groups (<italic toggle="yes">n</italic>&#8201;=&#8201;10). Group I represented the normal-control group. Group II represented the Bleo-control group. Groups III and IV received intra-tracheal Bleo followed by oral ECH (25 and 50&#160;mg/kg); respectively, for 1 month. Lung tissue contents of reduced glutathione (GSH), malondialdehyde (MDA), transforming growth factor-beta (TGF-&#946;), matrix metalloproteinases (MMP-2 &amp; MMP-9), tissue inhibitor of metalloproteinase 1 (TIMP-1), MMP-9/TIMP-1 ratio, collagen-1 and alpha-Smooth muscle actin (&#945;-SMA) were measured. NADPH oxidase 4 (NOX4), connective tissue growth factor (CTGF) and endothelin-1 (ET-1) genes were quantified using PCR. Moreover, lung tissue histopathological changes were screened. Intra-tracheal Bleo instillation resulted in significant increments in the lung tissue contents of MDA, TGF-&#946;, MMP-2 &amp; MMP-9, TIMP-1, MMP-9/TIMP-1 ratio, collagen-1 and &#945;-SMA. Moreover, Bleo significantly elevated the PCR expression of NOX4, CTGF and ET-1 genes in lung tissues and caused apparent lung tissue histopathological fibrotic changes. ECH treatment ameliorated all the aforementioned parameters and mitigated the lung tissue histopathological fibrotic changes induced by Bleo. The study highlighted for the first time the anti-oxidant, anti-inflammatory and anti-fibrotic effects of ECH against Bleo-induced pulmonary fibrosis in rats. The study suggests that these effects are mainly mediated via the modulation of Gelatinases, NOX4, ET-1 and CTGF. Accordingly, ECH is anticipated as a potential therapy to be added to the treatment regimen of pulmonary fibrosis.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Echinacea</kwd><kwd>Bleomycin</kwd><kwd>Lung fibrosis</kwd><kwd>NOX4</kwd><kwd>Endothelin-1</kwd><kwd>CTGF</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Biochemistry</kwd><kwd>Molecular biology</kwd><kwd>Cardiology</kwd><kwd>Diseases</kwd><kwd>Medical research</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Research Centre Egypt</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par28">Lung diseases are major worldwide causes of illness and death. Asthma, chronic obstructive pulmonary disease (COPD), pneumonia, idiopathic pulmonary fibrosis (IPF) and lung cancer are amongst the most frequent lung illnesses<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. IPF, previously described as cryptogenic fibrosing alveolitis, typically affects adults over 40 and is characterized by persistent inflammation of the pulmonary parenchyma<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Persistent alveolar inflammation leads to pulmonary toxicity, fibroblast activation, and subsequently fibrosis<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Every year, this lethal illness results in more than one million fatalities in the US and more than five million worldwide. To date, the root cause of IPF is not well defined. Few effective treatments for IPF are currently available<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Antiinflammatories, immunosuppressives and anti-inflammatory interleukins have largely failed to treat pulmonary fibrosis. Treatment approaches have changed to focus on anti-fibrotic agents as the pathogenic actions of fibrotic foci, along with fibroblast proliferation have come to light. The use of these drugs was mostly justified by data pointing to abnormalities in the extracellular matrix deposition, increased fibroblast proliferation, myofibroblast activation, and alveolar inflammatory cytokine imbalance in the lungs of patients suffering IPF<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par29">Recent investigations report that inflammatory cells can secrete specific growth factors, including epidermal growth factor, platelet-derived growth factor, along with tissue growth factor-beta1 (TGF-&#946;1). Alterations of intestinal microbiota may lead to inflammation<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Reactive oxygen species (ROS), pro-inflammatory cytokines, proteases, and peroxidases are also released, leading to lung tissue damage. Inflammation and lung injury are mostly caused by ROS, which is released by active leukocytes<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. TGF-1&#946; is the major player in IPF<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. In the lungs, TGF-1&#946; activates inflammatory cells, causing significant ROS production and release as well as damage to epithelial cells. Fibroblasts and myofibroblasts are formed from damaged epithelial cells. These fibroblasts and myofibroblasts build up in the alveolar wall where they deposit, multiply, and regenerate the extracellular matrix by producing extracellular collagen and alpha-smooth muscle actin. This leads to a positive loop causing the progression of fibrosis<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par30">Other causes of IPF include bacterial and viral infections, including the herpes virus, TB, rheumatoid arthritis, radiotherapy for cancer treatment, some mineral substances like asbestos and silica, along with side effects of some chemotherapeutic agents like Bleomycin (Bleo)<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>.</p><p id="Par31">Endothelin-1 (ET-1) is a potent vasoactive peptide that plays a multifaceted role in the pathogenesis of lung fibrosis via promoting fibroblast activation and inflammation. Its involvement in these processes makes it a key player in the development and progression of pulmonary fibrosis. Targeting ET-1 signaling may offer a promising therapeutic strategy for treating fibrosis, particularly when combined with other anti-fibrotic agents that address different aspects of the disease<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par32">The NADPH oxidases (NOXs) family has been linked to pulmonary fibrosis<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Recent data suggest that matrix metalloproteinases (MMPs), NOX4 and connective tissue growth factor (CTGF) are upregulated in many fibrotic disorders, including pulmonary fibrosis<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par33">Bleomycin is an antimicrobial drug used as a chemotherapeutic agent for the treatment of many cancers including lymphomas, cervical, vaginal, skin, rectal and pyloric cancers. The use of Bleo leads to increased oxidative stress mainly via reducing the antioxidant enzyme activities. The major side effects of Bleo include lung fibrosis characterized by the accumulation of inflammatory cells (lymphocytes, neutrophils, eosinophils and macrophages) in the bronchoalveolar lavage<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Bleo is widely used in animal models for the induction of lung inflammation and fibrosis<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par34">Echinacea (ECH), <italic toggle="yes">Echinacea purpurea</italic>, family Asteraceae, is a perennial blooming herb mainly present in many regions of the US, Canada, and Europe. It is cultivated for both its aesthetic appeal and its well-documented therapeutic virtues. ECH&#8217;s chemical makeup plays a variety of roles in influencing its action. The most important chemical constituents include high molecular weight polysaccharides, volatile terpenes, phenolic chemicals, glycoproteins, and derivatives of caffeic acid. ECH has wound-healing, immune-modulating, antiviral, anti-microbial and anti-inflammatory activities. Respiratory issues brought on by bacterial infections can be safely treated with it<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. ECH has recently been proposed as a potential herbal medicinal option for new coronaviruses, among many other herbal remedies<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>.</p><p id="Par35">Thus, the current work aims to evaluate the possible anti-oxidant and anti-fibrotic effects of ECH against Bleomycin-induced pulmonary fibrosis in rats. The molecular mechanisms underlying these effects will be evaluated, shedding light on the involvement of NOX-4 and ET-1/CTGF/MMPs signalling.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Animals</title><p id="Par36">Male albino Wistar rats (200&#8211;300&#160;g) were procured from the animal house of the National Research Centre (Cairo, Egypt) and allocated in plastic cages under controlled environmental conditions (24&#8201;&#177;&#8201;2&#160;&#176;C &amp; normal light/dark cycle) with food and water ad libitum. Rats were adapted to the experimental conditions for 7 days before starting the experiment.</p></sec><sec id="Sec4"><title>Ethical statement</title><p id="Par37">All experimental procedures adhere to the ARRIVE guidelines and were performed following the recommendations of the National Institutes of Health Guide for Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978) and performed as per the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Ethical approval was obtained from the Institutional Animal Ethics Committee (Medical Research Ethics Committee (MREC) of the NRC, Cairo, Egypt; Ethical Approval Number: 5411022023.</p></sec><sec id="Sec5"><title>Chemicals and kits</title><p id="Par38">Bleomycin vials (Bleocip 15<sup>&#174;</sup>) were purchased from Cipla Pharmaceutical Company (Mumbai, India). <italic toggle="yes">Echinacea purpurea</italic> (Immulant<sup>&#174;</sup>, 175&#160;mg capsules) was obtained from MEPACO-MEDIFOOD (Cairo, Egypt).</p><p id="Par39">Transforming growth factor-beta (TGF-&#946;; Catalog number: SL0709Ra), Matrix metalloproteinases 2 (MMP-2; Catalog number: SL0483Ra), Matrix metalloproteinases 9 (MMP-9; Catalog number: SL0490Ra), Tissue Inhibitor of metalloproteinase 1 (TIMP-1; Catalog number: SL0692Ra), Collagen-1 (Catalog number: SL0181Ra) and alpha-Smooth muscle actin (&#945;-SMA; Catalog number: SL0988Ra) were purchased from Sunlong Biotech Co., Ltd, China. All other chemicals were of the highest available analytical grade.</p></sec><sec id="Sec6"><title>Induction of pulmonary fibrosis</title><p id="Par40">Thiopental sodium was used to anesthetize rats (50&#160;mg/kg, i.p.), then pulmonary fibrosis was induced by a single Bleo dose (5&#160;mg/kg; intra-tracheal instillation). The trachea was exposed horizontally after a midline neck incision, and the position of the needle was modified until it completely entered the trachea before Bleo was injected. To ensure that Bleo was distributed uniformly throughout the lung tissues, rats were maintained in a vertical position and rotated numerous times<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p></sec><sec id="Sec7"><title>Experimental design</title><p id="Par42">Forty rats were randomly allocated into four groups (<italic toggle="yes">n</italic>&#8201;=&#8201;10). Group I received only saline (5 mL/kg; intra-tracheal), was sham-operated and represents the normal-control group. Pulmonary fibrosis was induced in the remaining groups using Bleo (5&#160;mg/kg). Group II represents the Bleo-control group that received only Bleo. Groups III and IV received intra-tracheal Bleo followed by oral ECH (25 and 50&#160;mg/kg); respectively, starting from day 1 for 1 month<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> illustrates a schematic flowchart of the study experimental design.</p><p id="Par43">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Schematic diagram of experimental design and treatment protocol.</p></caption><graphic id="d33e422" position="float" orientation="portrait" xlink:href="41598_2025_6559_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec8"><title>Biochemical analysis</title><p id="Par44">At the end of the experiment, rats were sacrificed by decapitation under Thiopental sodium anesthesia (50&#160;mg/kg, i.p). The lungs were excised and 0.3&#160;mg of each right lung was homogenized in 5% normal saline to obtain a 20% homogenate. The homogenate was centrifuged for 10&#160;min using a cooling centrifuge at -4<sup>&#176;</sup> c at 3000 r.p.m, and the supernatant was used for the biochemical analyses. The left lung was used for the histopathological examination.</p><p id="Par45">The concentrations of lipid peroxidation products Malondialdehyde (MDA) and reduced glutathione (GSH) were detected in lung homogenates spectrophotometrically at wavelengths 535&#160;nm and 412&#160;nm according to the methods by Nair and Turner (1984) and Ellman (1959)<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> and; respectively, as described before<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>.</p></sec><sec id="Sec9"><title>Quantitative real-time PCR gene expression of NOX4, CTGF and ET-1 in lung tissues</title><p id="Par46">Total RNA was extracted from rats` lung tissue homogenates using TRI reagent (Molecular Research Center Inc., Cincinnati, OH)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Quantification of the extracted RNA was done by spectro-photometry (JENWAY, USA) at 260&#160;nm. The obtained RNA is utilized for the assessment of NADPH oxidase 4 (NOX4), connective tissue growth factor (CTGF) and endothelin-1 (ET-1) gene expression levels with quantitative RT-PCR in agreement with the manufacturer`s protocol (GoTaq<sup>&#174;</sup> 1-Step RT-qPCR System). PCR primers were designed with Gene Runner Software (Hastings Software Inc., Hastings, NY, USA) with RNA sequences obtained from GenBank, using GAPDH as a housekeeping gene (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The obtained data were calculated using the 2&#8201;&#8722;&#8201;&#916;&#916; CT method<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.</p><p id="Par47">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Primer sequence of housekeeping and target genes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Gene</th><th align="left" colspan="1" rowspan="1">Forward primer</th><th align="left" colspan="1" rowspan="1">Reverse primer</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">NOX4</td><td align="left" colspan="1" rowspan="1">5&#8242;-AGTCAAACAGATGGGA-3&#8242;</td><td align="left" colspan="1" rowspan="1">5&#8242;-TGTCCCATATGAGTTGTT-3&#8242;</td></tr><tr><td align="left" colspan="1" rowspan="1">CTGF</td><td align="left" colspan="1" rowspan="1">5&#8242;-TGTGAAGACATACAGGGCTAA-3&#8242;</td><td align="left" colspan="1" rowspan="1">5&#8242;-GTTCTCACTTTGGTGGGATAG-3&#8242;</td></tr><tr><td align="left" colspan="1" rowspan="1">ET-1</td><td align="left" colspan="1" rowspan="1">5&#8242;-GAACATCTGTCCGGCTTCTAC-3&#8242;</td><td align="left" colspan="1" rowspan="1">5&#8242;-TATGGAATCTCCTGGCTCTCT-3&#8242;</td></tr><tr><td align="left" colspan="1" rowspan="1">GAPDH</td><td align="left" colspan="1" rowspan="1">5&#8242;-TGAACGGGAAGCTCACTGG-3&#8242;</td><td align="left" colspan="1" rowspan="1">5&#8242;-TCCACCACCCTGTTGCTGTA-3&#8242;</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec10"><title>Histopathological examination</title><p id="Par48">Lung specimens from all animals were dissected immediately after death and fixed in a 10% neutral-buffered formalin solution for at least 12&#160;h. All the specimens were washed and then dehydrated in ascending grades of alcohol, cleared in xylene and embedded in paraffin. Serial Sections&#160;3&#160;&#956;m thick were cut and stained with Haematoxylin and eosin for histopathological examination<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Images were captured using an image analysis system with Olympus CX41 light microscope and SC100 video camera attached to a computer system. Photomicrographs were taken at different magnifications and processed using Adobe Photoshop version8.0.</p><p id="Par49">Histopathological scoring of the H&amp;E tissue was done. Four histopathological categories were selected: (1) dilatation of the respiratory tract, (2) infiltration of inflammatory cells, (3) proliferation of respiratory epithelium, and (4) vascular congestion. The first three categories were assessed using a semi-quantitative scale (0 to 3), with 0 indicating no pathology and 3 indicating the most serious damage; the last category was graded from 0 to 1 based on the lack or presence of vascular congestion. The overall histopathological score of the lung was computed by adding the values given for each criterion<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>.</p></sec><sec id="Sec11"><title>Statistical analysis</title><p id="Par50">The results were presented as mean&#8201;&#177;&#8201;standard error of means. Shapiro-Wilk test was used for testing normality. A one-way analysis of variance (ANOVA), followed by <italic toggle="yes">Tukey&#8217;s</italic> post hoc test, was used to test the statistical significance. Bartlett&#8217;s test and Brown-Forsythe test were used for testing the homogeneity of variances. Statistics and graphical presentations were created using GraphPad prism<sup>&#174;</sup> software (version 9.00 for Windows, San Diego, CA, USA).</p></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title><italic toggle="yes">Echinacea ameliorates</italic> the oxidative stress parameters in Bleomycin-induced pulmonary fibrosis in rats</title><p id="Par51">Intra-tracheal Bleo instillation (5&#160;mg/kg) resulted in a decrease in lung tissue GSH contents (20.77&#8201;&#177;&#8201;0.859&#160;mg/mg of protein), accompanied by an increase in lung tissue MDA contents (86.66&#8201;&#177;&#8201;4.817 nmol/mg of protein) vs. the normal-control group. Oral ECH treatment (25 &amp;50&#160;mg/kg) caused a significant increase in lung tissue GSH contents to reach 37.17&#8201;&#177;&#8201;0.863 &amp; 49.87&#8201;&#177;&#8201;1.411; respectively, accompanied by a significant decrease in lung tissue MDA contents to reach 64.43&#8201;&#177;&#8201;1.808 &amp;52.38&#8201;&#177;&#8201;1.083 vs. the Bleo group, respectively. In addition, ECH treatment (50&#160;mg/kg) restored MDA and GSH contents to their normal levels (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par52">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Effects of <italic toggle="yes">Echinacea purpurea</italic> on lung tissue contents of (A) GSH and (B) MDA contents in Bleomycin-induced Pulmonary fibrosis in rats. Data is presented as the mean&#8201;&#177;&#8201;SE. Statistical significance was calculated using one-way ANOVA followed by <italic toggle="yes">Tukey&#8217;s</italic> test. (** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.01, **** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001).</p></caption><graphic id="d33e565" position="float" orientation="portrait" xlink:href="41598_2025_6559_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec14"><title><italic toggle="yes">Echinacea ameliorates</italic> the TGF-&#946;, MMP-2, MMP-9 and TIMP-1 in Bleomycin-induced pulmonary fibrosis in rats</title><p id="Par54">Intra-tracheal Bleo instillation (5&#160;mg/kg) elicited a significant rise in lung tissue TGF-&#946;, MMP-2, MMP-9 and TIMP-1 contents to reach 52.77&#8201;&#177;&#8201;2.176, 14.56&#8201;&#177;&#8201;0.245, 13.72&#8201;&#177;&#8201;0.586 &amp; 1.86&#8201;&#177;&#8201;0.058 ng/mg of protein, respectively vs. the normal-control group.</p><p id="Par55">Oral ECH treatment (25&#160;mg/kg) elicited a reduction in lung tissue TGF-&#946;, MMP-2, MMP-9 and TIMP-1 contents to reach 38.42&#8201;&#177;&#8201;0.807, 10.24&#8201;&#177;&#8201;0.302, 8.68&#8201;&#177;&#8201;0.547 &amp; 1.64&#8201;&#177;&#8201;0.026 respectively vs. the Bleo group. Similarly, Oral ECH treatment (50&#160;mg/kg) elicited a reduction in lung tissue TGF-&#946;, MMP-2, MMP-9 and TIMP-1 contents to reach 23.19&#8201;&#177;&#8201;0.622, 8.66&#8201;&#177;&#8201;0.181, 5.8&#8201;&#177;&#8201;0.458 &amp;1.29&#8201;&#177;&#8201;0.024, respectively vs. the Bleo group. Moreover, ECH treatment (50&#160;mg/kg) restored MMP9 content to its normal levels (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par56">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Effects of <italic toggle="yes">Echinacea purpurea</italic> on lung tissue contents of (A) TGF-&#946;, (B) MMP-2, (C) MMP-9 and (D) TIMP-1 contents in Bleomycin-induced Pulmonary fibrosis in rats. Data is presented as the mean&#8201;&#177;&#8201;SE. Statistical significance was calculated using one-way ANOVA followed by <italic toggle="yes">Tukey&#8217;s</italic> test. (**** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001, *** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, ** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.01, * at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05).</p></caption><graphic id="d33e607" position="float" orientation="portrait" xlink:href="41598_2025_6559_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec15"><title><italic toggle="yes">Echinacea ameliorates</italic> the MMP-9/TIMP-1 ratio in Bleomycin-induced pulmonary fibrosis in rats</title><p id="Par59">Intra-tracheal Bleo instillation (5&#160;mg/kg) caused a 142% rise in the MMP-9/TIMP-1 ratio vs. the normal-control group. Oral ECH treatment (25 &amp;50&#160;mg/kg) elicited a 69% and 63% reduction in MMP-9/TIMP-1 ratio vs. the Bleo group. Noticeably, ECH treatment (50&#160;mg/kg) returned MMP9 /TIMP-1 to its normal ratio (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par60">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Effects of <italic toggle="yes">Echinacea purpurea</italic> on lung tissue MMP-9/TIMP-1 ratio in Bleomycin-induced Pulmonary fibrosis in rats. Data is presented as the mean&#8201;&#177;&#8201;SE. Statistical significance was calculated using one-way ANOVA followed by <italic toggle="yes">Tukey&#8217;s</italic> test. (*** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, ** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.01, * at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05).</p></caption><graphic id="d33e643" position="float" orientation="portrait" xlink:href="41598_2025_6559_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec16"><title><italic toggle="yes">Echinacea ameliorates</italic> collagen-1 and &#945;-SMA in Bleomycin-induced pulmonary fibrosis in rats</title><p id="Par61">Intra-tracheal Bleo instillation (5&#160;mg/kg) increased lung tissue collagen-1 and &#945;-SMA contents to reach 25.27&#8201;&#177;&#8201;0.805 &amp; 67.44&#8201;&#177;&#8201;1.949 ng/mg of protein, respectively vs. the normal-control group. Oral ECH treatment (25&#160;mg/kg) caused a reduction in lung tissue collagen-1 and &#945;-SMA vs. the Bleo group to reach 15.56&#8201;&#177;&#8201;0.577 &amp; 62.06&#8201;&#177;&#8201;1.56, respectively. Similarly, ECH treatment (50&#160;mg/kg) reduced the lung tissue collagen-1 and &#945;-SMA vs. the Bleo group to reach 9.78&#8201;&#177;&#8201;1.127 &amp; 28.99&#8201;&#177;&#8201;0.581, respectively. In addition, ECH treatment (50&#160;mg/kg) returned lung tissue collagen-1 to its normal level (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par62">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Effects of <italic toggle="yes">Echinacea purpurea</italic> on lung tissue contents of (A) Collagen-1 and (B) &#945;-SMA contents in Bleomycin-induced Pulmonary fibrosis in rats. Data is presented as the mean&#8201;&#177;&#8201;SE. Statistical significance was calculated using one-way ANOVA followed by <italic toggle="yes">Tukey&#8217;s</italic> test. (**** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001, *** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, ** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.01, * at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05).</p></caption><graphic id="d33e683" position="float" orientation="portrait" xlink:href="41598_2025_6559_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec17"><title>Quantitative real-time PCR gene expression of NOX4, CTGF and ET-1 in lung tissues</title><p id="Par64">Lung tissue qRT PCR gene expression of NOX4, CTGF and ET-1 were significantly raised to 2.95&#8201;&#177;&#8201;0.05, 3.62&#8201;&#177;&#8201;0.033&amp; 3.02&#8201;&#177;&#8201;0.052 in the Bleo-control group vs. the normal-control group; respectively.</p><p id="Par65">Oral ECH treatment (25&#160;mg/kg) decreased the lung tissue gene expression of NOX4, CTGF and ET-1 vs. the Bleo group to reach 2.14&#8201;&#177;&#8201;0.046, 2.48&#8201;&#177;&#8201;0.033 &amp; 2.4&#8201;&#177;&#8201;0.04, respectively. Similarly, ECH treatment (50&#160;mg/kg) decreased the lung tissue gene expression of NOX4, CTGF and ET-1 vs. the Bleo group to reach 1.28&#8201;&#177;&#8201;0.052, 1.66&#8201;&#177;&#8201;0.046 &amp;1.44&#8201;&#177;&#8201;0.061; respectively (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).</p><p id="Par66">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Effects of <italic toggle="yes">Echinacea purpurea</italic> on lung tissue qRT PCR gene expression of (A) NOX4, (B) CTGF and (C) ET-1 in Bleomycin-induced Pulmonary fibrosis in rats. Data is presented as the mean&#8201;&#177;&#8201;SE. Statistical significance was calculated using one-way ANOVA followed by <italic toggle="yes">Tukey&#8217;s</italic> test. ( **** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001).</p></caption><graphic id="d33e712" position="float" orientation="portrait" xlink:href="41598_2025_6559_Fig6_HTML.jpg"/></fig>
</p></sec><sec id="Sec18"><title>Histopathological examination of lung tissues</title><p id="Par68">Figure <xref rid="Fig7" ref-type="fig">7</xref> illustrates the histopathological pictures of the lung tissues of different experimental groups. Pictures of lung tissues of normal-control rats revealed a normal histopathological structure of lungs, bronchia and bronchioles. The alveolar sacs are separated by alveolar septa, comprising alveolar lining cells and thin-walled capillaries. The bronchioles have intact walls with normal-looking ciliated columnar epithelium and normal-looking bronchial vessels (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>A).</p><p id="Par69">Intra-tracheal Bleo instillation (5&#160;mg/kg) caused substantial lung tissue histopathological alterations as shown by the destruction of the alveolar sacs and bronchioles. the alveolar sacs seem totally destroyed. The bronchioles have damaged walls and inflammatory cells infiltrate, accompanied by attenuated alveolar vessels can be noticed (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>B).</p><p id="Par70">Oral ECH treatment (25&#160;mg/kg) resulted in a dose-dependent improvement of lung tissues, bronchi and bronchioles. The alveolar sacs are separated by alveolar septa. The bronchioles have intact walls and the bronchial vessels look almost normal (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>C).</p><p id="Par71">Oral ECH treatment (50&#160;mg/kg) resulted in a normal-looking architecture of the lung.tissues, bronchia and bronchioles. The alveolar sacs are separated by alveolar septa, comprising alveolar lining cells and thin-walled capillaries. The bronchioles have intact walls with normal-looking ciliated columnar epithelium. Also, normal-looking bronchial vessels can be noticed (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>D).</p><p id="Par72">The severity of alterations in the lung was blindly scored microscopically, and the histopathological scoring of the stained lung tissue is presented in Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>E.</p><p id="Par73">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Effects of <italic toggle="yes">Echinacea purpurea</italic> on the histological pictures of lung tissues in rats. <bold>(A)</bold> A photomicrography of lung tissue of the normal-control group showing normal-looking architecture. The alveolar sacs (A) are separated by alveolar septa, the bronchioles (B) have intact walls (Red arrows). <bold>(B)</bold> A photomicrography of lung tissue of the Bleomycin-control group showing damaged bronchioles, inflammatory cells infiltrate (INF) and attenuated alveolar vessels (Yellow arrow). <bold>(C)</bold> A photomicrography of lung tissue of the group treated orally with Echinacea (25&#160;mg/kg) showing alveolar sacs (A) separated by alveolar septa. The bronchioles (B) have intact walls and the bronchial vessels look almost normal (Red arrows). <bold>(D)</bold> A photomicrography of lung tissue of the group treated orally with Echinacea (50&#160;mg/kg) showing alveolar sacs (A) are separated by alveolar septa, bronchioles (B) have intact walls and normal-looking bronchial vessels (Red arrows) (H&amp;E 16x). <bold>(E)</bold> Histopathological scoring of lung tissue of all groups. Data is presented as the mean&#8201;&#177;&#8201;SE. Statistical significance was calculated using one-way ANOVA followed by <italic toggle="yes">Tukey&#8217;s</italic> test. (**** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001, *** at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, * at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05).</p></caption><graphic id="d33e784" position="float" orientation="portrait" xlink:href="41598_2025_6559_Fig7_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par74">IPF is a deadly chronic fibroproliferative lung disease with idiopathic origins. Bleo-induced pulmonary fibrosis is considered one of the most commonly used in vivo models for the induction of lung fibrosis. Bleo induces cytotoxicity and blocks the synthesis of proteins and DNA, leading to oxidative stress, inflammation and fibrosis of the lung tissues<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. The current study aims to evaluate the possible protective effects of ECH against Bleomycin-induced pulmonary fibrosis.</p><p id="Par75">In the present study, Intra-tracheal Bleo instillation (5&#160;mg/kg) resulted in significant oxidative stress as manifested by elevated lipid peroxidation products calculated as MDA and reduced the lung tissue contents of GSH. Previous studies linked Bleo administration to the production of oxidative stress parameters such as lipid peroxidation end products (MDA). Moreover, Bleo use decreased the natural antioxidants in the lung tissues (e.g., superoxide dismutase, catalase and GSH), eventually initiating cellular injury<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>.</p><p id="Par76">Bleo instillation in the current work caused a significant inflammation as manifested by peaking of lung tissue TGF-&#946;. Cellular injury caused by oxidative stress initiates inflammation via the activation of numerous proinflammatory cytokines and growth factors. Inflammation then leads to the pathophysiological mechanisms of pulmonary fibrosis. TGF-&#946; is a pro-fibrotic growth factor that is considered the major player in pulmonary fibrosis where it leads to substantial inflammation, dysregulated cellular repair and promotes progressive fibrosis, particularly in the early phase<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. TGF-&#946; also suppresses natural autophagy and amplifies the tissue damage response to further promote inflammation and fibrosis via enhancement of fibroblast activation<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par77">Additionally, the current work demonstrated that intra-tracheal Bleo instillation caused an elevation of lung tissue MMP-2, MMP-9 TIMP-1, collagen-1 and &#945;-SMA contents along with MMP-9/TIMP-1 ratio. Bleo also caused a significant increment in PCR expression of NOX4, CTGF as well as ET-1 in lung tissues. Moreover, the histopathological examination of lung tissues of rats treated intratracheally with Bleo showed entirely destructed alveolar sacs, damaged walls of the bronchioles, and attenuated alveolar vessels accompanied by inflammatory cell infiltrate. Previous studies reported that Bleo use causes alveolar inflammation that increases over time. On day 7, fibroblast proliferation was stimulated, inflammation began to worsen, and collagen production surged. On day 14, the alveolar structure was destroyed and collagen began to accumulate widely, displaying the first pathological signs of pulmonary fibrosis<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. The homeostasis of the lung&#8217;s extracellular matrix (ECM) is tightly regulated under normal circumstances. However, in idiopathic pulmonary fibrosis, this homeostasis is seriously dysregulated where ECM accumulation occurs, leading to progressive fibrosis<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Lung fibrosis is characterized by an excessive buildup of ECM proteins in the lung interstitium, which is a major cause of lung stiffness, shortness of breath, and ultimately respiratory failure. The ECM sustains mechanical support and functions as a connector between cells, therefore it exerts a crucial role in preserving typical cellular structure and function<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. The production and deposition of collagen, fibronectin and &#945;-SMA are all increased by abnormal fibroblast activation. The interstitium became rigid as a result of excessive ECM production and deposition<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Because of their ability to remove ECM, matrix metalloproteinases have acquired considerable attention in the scope of IPF pathogenesis. MMPs are extracellular enzymes that are initially released as inactive zymogens. MMPs and their tissue inhibitors (TIMPs) are the chief enzymes involved in ECM metabolism<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Gelatin, elastin, and other various forms of collagen are particularly susceptible to degradation by MMP-2 and MMP-9, commonly defined as Gelatinases A and B; respectively. Both proteases are found in the lungs of idiopathic pulmonary fibrosis patients and are expressed by bronchial, bronchiolar fibroblasts, fibrocytes, and alveolar epithelial cells. The fact that the deletion of MMP-2 may be functionally compensated for by MMP-9 assesses a direct contribution of one single gelatinase to lung fibrogenesis rather challenging<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. TIMP-1 is a specific tissue inhibitor of MMP-9 while TIMP-2 is a specific tissue inhibitor of MMP-2<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. A balanced MMP/TIMP ratio in the lung tissue is essential for balancing the synthesis and breakdown of the ECM<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Numerous studies reported the elevation of gelatinases and their tissue inhibitors in lung fibrosis induced experimentally via lipopolysaccharide<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and paraquat<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Also, many studies demonstrated elevation of MMP-2, MMP-9 and TIMP-1 in Bleo-induced lung fibrosis<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. Similar to the current work, Bai et al.. (2020) reported that Bleo instillation was linked to elevated expressions of fibrosis-related biomarkers, viz., &#945;-SMA and collagens I, II &amp;III. The key ECM elements of the lungs are collagen I and collagen III, which are important fibroblast protein signals. Collagens are markedly increased in lung fibrosis, with collagen I being the most markedly accentuated member of the group<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p><p id="Par78">Seven NOX homologs make up the NADPH oxidases (NOXs) family. NOX4 has been linked to many fibrotic disorders, including hepatic, renal, cardiac, dermal and pulmonary fibrosis. It is well documented that NOX4, along with the pro-fibrotic and pro-proliferative endothelin-1 (ET-1) and connective tissue growth factor (CTGF), are all considerably upregulated in pulmonary fibrosis<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. NOX4 is a key player in the pathophysiology of IPF. Moreover, it is excessively expressed in the lungs post-Bleo administration in experimental animals and in humans of BLM-subjugated. TGF-&#946; is the major contributor to NOX4 expression. &#945;-SMA and collagen expression are modulated by NOX4 in lung fibroblasts<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Additionally, TGF-&#946; induces the expression of two crucial matricellular proteins, CTGF and ET-1, which work downstream of this cytokine to stimulate fibrogenic responses such as myofibroblast development, collagen synthesis, and &#945;-SMA expression. There is accumulating evidence that CTGF and ET-1 are increased during fibrogenesis. The CTGF and ET-1 may be possible targets for anti-fibrotic therapy, according to a growing body of research showing that TGF-&#946;, CTGF, and ET-1 expressions are cooperatively increased within the lung tissue in IPF<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Many studies report a rise in CTGF and ET-1 expression levels in pulmonary tissues in response to Bleo administration<sup><xref ref-type="bibr" rid="CR40">40</xref>&#8211;<xref ref-type="bibr" rid="CR42">42</xref></sup>.</p><p id="Par79">Recent studies demonstrate that in pulmonary fibrosis, ET-1, CTGF, and the balance between MMPs and their tissue inhibitors TIMPs interact in a complex crosstalk that drives the progression of the disease<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. ET-1, a potent vasoconstrictor and pro-fibrotic factor, promotes the activation of fibroblasts and their differentiation into myofibroblasts, which are key contributors to excessive ECM deposition. ET-1 also stimulates the expression of CTGF, a critical mediator of fibrosis that enhances fibroblast proliferation and collagen synthesis<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Meanwhile, the MMPs, particularly MMP-2 and MMP-9, are responsible for ECM degradation, but their activity is tightly regulated by TIMPs. In fibrotic lungs, the balance between MMPs and TIMPs is often skewed towards increased TIMP levels, resulting in reduced ECM turnover and excessive collagen accumulation. The interplay between ET-1 and CTGF exacerbates this imbalance by further promoting ECM production and inhibiting its degradation, thus amplifying the fibrotic response and contributing to the progressive nature of pulmonary fibrosis<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>.</p><p id="Par80">Since medicinal plants have a variety of chemical components and exhibit a variety of biological functions, they are frequently employed in medicine as alternative therapies and/or supplementary therapeutic regimens. <italic toggle="yes">Echinacea purpurea</italic> (ECH) is a herbaceous perennial flowering plant that has antiviral, anti-fibrotic as well as antioxidant properties<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p id="Par81">In the present work, ECH treatment (25 and 50&#160;mg/kg; p.o.) resulted in a significant reduction in the lung tissue contents of MDA, TGF-&#946;, MMP-2, MMP-9, TIMP-1, MMP-9/TIMP-1 ratio, collagen-1 and &#945;-SMA. ECH treatment also caused a significant increment in the lung tissue GSH contents. Moreover, ECH significantly reduced the PCR expression of NOX4, CTGF as well as ET-1 in lung tissues and mitigated the lung tissue histopathological fibrotic changes induced by Bleo administration. Taken together, these results suggest that ECH ameliorates oxidative Stress, inflammation, histopathological changes and lung fibrosis in Bleo-induced pulmonary fibrosis in rats.</p><p id="Par82">Few studies explored the anti-fibrotic effects of ECH on lung fibrosis. In one study, ECH is reported to have anti-inflammatory properties and thus mitigates lipopolysaccharide-induced lung damage via the reduction of inflammation, apoptosis, and the activation of the TLR4/NF-&#954;B signaling pathway<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Guo et al.. (2023) reported that ECH suppresses NO Production in lipopolysaccharide-induced lung injury via the inhibition of NLRP3<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Moreover, ECH is reported to minimize IL-6 and TNF-&#945; concentrations in patients suffering from viral and bacterial respiratory infections. ECH boosts antioxidant capacity in many tissues including the brain liver, heart, kidneys and lungs. ECH also inhibits the proinflammatory cytokines, viz., Nrf2, HO-1 and NF-&#954;B. ROS production, inflammation, cell proliferation and NADPH oxidase expression are also modulated by ECH<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Another recent study reported a significant improvement in lung histopathological changes post-treatment with ECH in diabetic male rats as manifested by the substantial reduction in the interalveolar septal thickness, collagen fibers percentage as well as caspase-3 expression in lung tissue<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>.</p><p id="Par83">The current study, while demonstrating promising anti-fibrotic effects of ECH in Bleo-induced pulmonary fibrosis rat model, is subject to several limitations that may affect the generalizability and translational potential of its findings. Species-specific differences between rats and humans limit the direct applicability of results to human clinical settings. The absence of the effect of environmental and confounding factors like concurrent diseases also limits the generalizability of the study. The study also lacks a comprehensive dose-response assessment, evaluating only two ECH doses (25 and 50&#160;mg/kg). Importantly, no human data are available to support clinical translation, and the short-term design fails to assess long-term efficacy or safety. Addressing these limitations in future research will be crucial to validating ECH as a viable therapeutic agent for pulmonary fibrosis.</p><p id="Par84">To the best of the author&#8217;s knowledge, this is the first study into the potential therapeutic benefits of ECH on Bleo-induced lung fibrosis. Furthermore, the potential molecular mechanisms underlying these beneficial actions have been explored.</p></sec><sec id="Sec20"><title>Conclusion</title><p id="Par85">Taken together, we have revealed the potential anti-oxidant, anti-inflammatory and anti-fibrotic effects of <italic toggle="yes">Echinacea purpurea</italic> (ECH) against Bleomycin-induced pulmonary fibrosis in Rats. ECH treatment resulted in a significant reduction in the lung tissue contents of MDA, TGF-&#946;, gelatinases (MMP-2&amp; MMP-9) along with their inhibitor (TIMP-1), MMP-9/TIMP-1 ratio, collagen-1 and &#945;-SMA. ECH treatment also caused a significant increment in the lung tissue GSH contents. Moreover, ECH significantly reduced the PCR expression of NOX4, CTGF as well as ET-1 in lung tissues and mitigated the lung tissue histopathological fibrotic changes induced by Bleo administration. Accordingly, ECH is anticipated as a potential therapy due to its anti-oxidant, anti-inflammatory and anti-fibrotic effects and thus it can be added to the treatment regimen of pulmonary fibrosis. Further investigations are necessary to consider adding ECH to the treatment protocol for pulmonary fibrosis.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>IPF</term><def><p id="Par2">Idiopathic pulmonary fibrosis</p></def></def-item><def-item><term>Bleo</term><def><p id="Par3">Bleomycin</p></def></def-item><def-item><term>ECH</term><def><p id="Par4">Echinacea purpurea</p></def></def-item><def-item><term>COPD</term><def><p id="Par5">Chronic obstructive pulmonary disease</p></def></def-item><def-item><term>TGF-&#946;1</term><def><p id="Par6">Tissue growth factor-beta1</p></def></def-item><def-item><term>ROS</term><def><p id="Par7">Reactive oxygen species</p></def></def-item><def-item><term>MMP-2</term><def><p id="Par8">Matrix metalloproteinases 2</p></def></def-item><def-item><term>MMP-9</term><def><p id="Par9">Matrix metalloproteinases 9</p></def></def-item><def-item><term>TIMP-1</term><def><p id="Par10">Tissue Inhibitor of metalloproteinase 1</p></def></def-item><def-item><term>&#945;-SMA</term><def><p id="Par11">Alpha-Smooth muscle actin</p></def></def-item><def-item><term>MDA</term><def><p id="Par12">Malondialdehyde</p></def></def-item><def-item><term>GSH</term><def><p id="Par13">Reduced glutathione</p></def></def-item><def-item><term>NOX4</term><def><p id="Par14">NADPH oxidase 4</p></def></def-item><def-item><term>CTGF</term><def><p id="Par15">Connective tissue growth factor</p></def></def-item><def-item><term>ET-1</term><def><p id="Par16">Endothelin-1</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>The authors declare that all data were generated in-house and that no paper mill was used. All authors contributed equally to the study&#8217;s conception &amp; design. A.S. participated in the practical experimentation, carried out the statistical analyses and revised the manuscript. R. E. participated in the practical experimentation. S. A. participated in the practical PCR experimentation. R.M. participated in the practical experimentation, carried out the statistical analyses and wrote the manuscript. The final version of the manuscript was reviewed and approved by all authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). The authors declare no external funding.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All Data will be available upon request. Please contact the corresponding author R.E. Mostafa if someone wants to request the data from this study.</p></notes><notes><title>Declarations</title><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par86">The authors declare no competing interests.</p></notes><notes id="FPar3"><title>Ethical statement</title><p id="Par87">All experimental procedures adhere to the ARRIVE guidelines and were performed following the recommendations of the National Institutes of Health Guide for Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978) and performed as per the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Ethical approval was obtained from the Institutional Animal Ethics Committee (Medical Research Ethics Committee (MREC) of the NRC, Cairo, Egypt; Ethical Approval Number: 5411022023.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmud</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients</article-title><source>Brief. Bioinform.</source><year>2021</year><volume>22</volume><issue>5</issue><fpage>bbab115</fpage><pub-id pub-id-type="pmid">33847347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbab115</pub-id><pub-id pub-id-type="pmcid">PMC8083324</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Mahmud, S. H. et al. Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients. <italic toggle="yes">Brief. Bioinform.</italic><bold>22</bold> (5), bbab115 (2021).<pub-id pub-id-type="pmid">33847347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbab115</pub-id><pub-id pub-id-type="pmcid">PMC8083324</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>RG</given-names></name><etal/></person-group><article-title>An official American thoracic society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2017</year><volume>56</volume><issue>5</issue><fpage>667</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">28459387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1165/rcmb.2017-0096ST</pub-id><pub-id pub-id-type="pmcid">PMC5800895</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Jenkins, R. G. et al. An official American thoracic society workshop report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis. <italic toggle="yes">Am. J. Respir. Cell Mol. Biol.</italic><bold>56</bold> (5), 667&#8211;679 (2017).<pub-id pub-id-type="pmid">28459387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1165/rcmb.2017-0096ST</pub-id><pub-id pub-id-type="pmcid">PMC5800895</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gad</surname><given-names>E</given-names></name><etal/></person-group><article-title>The anti-fibrotic and anti-inflammatory potential of bone marrow&#8211;derived mesenchymal stem cells and nintedanib in Bleomycin-induced lung fibrosis in rats</article-title><source>Inflammation</source><year>2020</year><volume>43</volume><issue>1</issue><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">31646446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-019-01101-2</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Gad, E. et al. The anti-fibrotic and anti-inflammatory potential of bone marrow&#8211;derived mesenchymal stem cells and nintedanib in Bleomycin-induced lung fibrosis in rats. <italic toggle="yes">Inflammation</italic><bold>43</bold> (1), 123&#8211;134 (2020).<pub-id pub-id-type="pmid">31646446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-019-01101-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yousefi-Manesh</surname><given-names>H</given-names></name><etal/></person-group><article-title>Protective effect of Dapsone against Bleomycin-induced lung fibrosis in rat</article-title><source>Exp. Mol. Pathol.</source><year>2022</year><volume>124</volume><fpage>104737</fpage><pub-id pub-id-type="pmid">34953919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexmp.2021.104737</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Yousefi-Manesh, H. et al. Protective effect of Dapsone against Bleomycin-induced lung fibrosis in rat. <italic toggle="yes">Exp. Mol. Pathol.</italic><bold>124</bold>, 104737 (2022).<pub-id pub-id-type="pmid">34953919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yexmp.2021.104737</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><issue>3</issue><fpage>1192</fpage><pub-id pub-id-type="pmid">33391530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.48152</pub-id><pub-id pub-id-type="pmcid">PMC7738894</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Pan, T. et al. Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis. <italic toggle="yes">Theranostics</italic><bold>11</bold> (3), 1192 (2021).<pub-id pub-id-type="pmid">33391530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.48152</pub-id><pub-id pub-id-type="pmcid">PMC7738894</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korotkyi</surname><given-names>O</given-names></name><etal/></person-group><article-title>The gut microbiota of rats under experimental osteoarthritis and administration of chondroitin sulfate and probiotic</article-title><source>Mikrobiol Z.</source><year>2020</year><volume>82</volume><issue>6</issue><fpage>64</fpage><lpage>73</lpage></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Korotkyi, O. et al. The gut microbiota of rats under experimental osteoarthritis and administration of chondroitin sulfate and probiotic. <italic toggle="yes">Mikrobiol Z.</italic><bold>82</bold> (6), 64&#8211;73 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Song, S. et al. <italic toggle="yes">Intracellular hydroxyproline imprinting following resolution of Bleomycin-induced pulmonary fibrosis</italic>. <italic toggle="yes">Eur. Respir. J.</italic>, <bold>59</bold>(5). (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00864-2021</pub-id><pub-id pub-id-type="pmcid">PMC9068975</pub-id><pub-id pub-id-type="pmid">34561295</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blobe</surname><given-names>GC</given-names></name><name name-style="western"><surname>Schiemann</surname><given-names>WP</given-names></name><name name-style="western"><surname>Lodish</surname><given-names>HF</given-names></name></person-group><article-title>Role of transforming growth factor &#946; in human disease</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>342</volume><issue>18</issue><fpage>1350</fpage><lpage>1358</lpage><pub-id pub-id-type="pmid">10793168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200005043421807</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Blobe, G. C., Schiemann, W. P. &amp; Lodish, H. F. Role of transforming growth factor &#946; in human disease. <italic toggle="yes">N. Engl. J. Med.</italic><bold>342</bold> (18), 1350&#8211;1358 (2000).<pub-id pub-id-type="pmid">10793168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM200005043421807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Meng, L. et al. <italic toggle="yes">Yangyin Yiqi mixture ameliorates Bleomycin-induced pulmonary fibrosis in rats through inhibiting TGF-1/Smad pathway and epithelial to mesenchymal transition.</italic> Evidence-based Complementary and Alternative Medicine, 2019. (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/2710509</pub-id><pub-id pub-id-type="pmcid">PMC6335662</pub-id><pub-id pub-id-type="pmid">30719057</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chioma</surname><given-names>OS</given-names></name><name name-style="western"><surname>Drake</surname><given-names>WP</given-names></name></person-group><article-title>Focus: infectious diseases: role of microbial agents in pulmonary fibrosis</article-title><source>Yale. J. Biol. Med.</source><year>2017</year><volume>90</volume><issue>2</issue><fpage>219</fpage><pub-id pub-id-type="pmid">28656009</pub-id><pub-id pub-id-type="pmcid">PMC5482299</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Chioma, O. S. &amp; Drake, W. P. Focus: infectious diseases: role of microbial agents in pulmonary fibrosis. <italic toggle="yes">Yale. J. Biol. Med.</italic><bold>90</bold> (2), 219 (2017).<pub-id pub-id-type="pmid">28656009</pub-id><pub-id pub-id-type="pmcid">PMC5482299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulito-Cueto</surname><given-names>V</given-names></name><etal/></person-group><article-title>Endothelin-1 as a biomarker of idiopathic pulmonary fibrosis and interstitial lung disease associated with autoimmune diseases</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><issue>2</issue><fpage>1275</fpage><pub-id pub-id-type="pmid">36674789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24021275</pub-id><pub-id pub-id-type="pmcid">PMC9862125</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Pulito-Cueto, V. et al. Endothelin-1 as a biomarker of idiopathic pulmonary fibrosis and interstitial lung disease associated with autoimmune diseases. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>24</bold> (2), 1275 (2023).<pub-id pub-id-type="pmid">36674789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24021275</pub-id><pub-id pub-id-type="pmcid">PMC9862125</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>J</given-names></name><name name-style="western"><surname>Chakraborti</surname><given-names>T</given-names></name><name name-style="western"><surname>Chakraborti</surname><given-names>S</given-names></name></person-group><article-title>Role of NADPH Oxidase-Induced oxidative stress in matrix Metalloprotease-Mediated lung diseases</article-title><source>Oxidative Stress Lung Diseases: Volume</source><year>2020</year><volume>2</volume><fpage>75</fpage><lpage>101</lpage></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Sarkar, J., Chakraborti, T. &amp; Chakraborti, S. Role of NADPH Oxidase-Induced oxidative stress in matrix Metalloprotease-Mediated lung diseases. <italic toggle="yes">Oxidative Stress Lung Diseases: Volume</italic>. <bold>2</bold>, 75&#8211;101 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhi</surname><given-names>X</given-names></name><etal/></person-group><article-title>Therapeutic potential of Angelica sinensis in addressing organ fibrosis: a comprehensive review</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>173</volume><fpage>116429</fpage><pub-id pub-id-type="pmid">38490157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2024.116429</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Zhi, X. et al. Therapeutic potential of Angelica sinensis in addressing organ fibrosis: a comprehensive review. <italic toggle="yes">Biomed. Pharmacother.</italic><bold>173</bold>, 116429 (2024).<pub-id pub-id-type="pmid">38490157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2024.116429</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Hemmati, A. A. et al. <italic toggle="yes">Protective effects of Morin against Bleomycin-Induced pulmonary fibrosis in mice</italic>. <italic toggle="yes">Jundishapur J. Nat. Pharm. Prod.</italic>, <bold>14</bold>(4). (2019).<pub-id pub-id-type="pmcid">PMC3941905</pub-id><pub-id pub-id-type="pmid">24624192</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Mostafa, R. E., Shaffie, N. M. &amp; Allam, R. M. <italic toggle="yes">Protective effects of Royal jelly and Echinacea against moxifloxacin-induced renal and hepatic injury in rats</italic>. <italic toggle="yes">Drug Chem. Toxicol.</italic>, : pp. 1&#8211;10. (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01480545.2022.2141773</pub-id><pub-id pub-id-type="pmid">36322409</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meeran</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Can Echinacea be a potential candidate to target immunity, inflammation, and infection-The trinity of coronavirus disease 2019</article-title><source>Heliyon</source><year>2021</year><volume>7</volume><issue>2</issue><fpage>e05990</fpage><pub-id pub-id-type="pmid">33585706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2021.e05990</pub-id><pub-id pub-id-type="pmcid">PMC7870107</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Meeran, M. N. et al. Can Echinacea be a potential candidate to target immunity, inflammation, and infection-The trinity of coronavirus disease 2019. <italic toggle="yes">Heliyon</italic><bold>7</bold> (2), e05990 (2021).<pub-id pub-id-type="pmid">33585706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2021.e05990</pub-id><pub-id pub-id-type="pmcid">PMC7870107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Bayramo&#287;lu, G. et al. <italic toggle="yes">The effect of Echinacea on kidney and liver after experimental renal ischemia/reperfusion injury in the rats.</italic> (2011).</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>V</given-names></name><name name-style="western"><surname>Turner</surname><given-names>GA</given-names></name></person-group><article-title>The thiobarbituric acid test for lipid peroxidation: structure of the adduct with malondialdehyde</article-title><source>Lipids</source><year>1984</year><volume>19</volume><issue>10</issue><fpage>804</fpage><lpage>805</lpage></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Nair, V. &amp; Turner, G. A. The thiobarbituric acid test for lipid peroxidation: structure of the adduct with malondialdehyde. <italic toggle="yes">Lipids</italic><bold>19</bold> (10), 804&#8211;805 (1984).</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellman</surname><given-names>GL</given-names></name></person-group><article-title>Tissue sulfhydryl groups</article-title><source>Arch. Biochem. Biophys.</source><year>1959</year><volume>82</volume><issue>1</issue><fpage>70</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">13650640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0003-9861(59)90090-6</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ellman, G. L. Tissue sulfhydryl groups. <italic toggle="yes">Arch. Biochem. Biophys.</italic><bold>82</bold> (1), 70&#8211;77 (1959).<pub-id pub-id-type="pmid">13650640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0003-9861(59)90090-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asaad</surname><given-names>GF</given-names></name><name name-style="western"><surname>Mostafa</surname><given-names>RE</given-names></name></person-group><article-title>Lactoferrin mitigates ethanol-induced gastric ulcer via modulation of ROS/ICAM-1/Nrf2 signaling pathway in Wistar rats</article-title><source>Iran. J. Basic. Med. Sci.</source><year>2022</year><volume>25</volume><issue>12</issue><fpage>1522</fpage><lpage>1527</lpage><pub-id pub-id-type="pmid">36544526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22038/IJBMS.2022.66823.14656</pub-id><pub-id pub-id-type="pmcid">PMC9742561</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Asaad, G. F. &amp; Mostafa, R. E. Lactoferrin mitigates ethanol-induced gastric ulcer via modulation of ROS/ICAM-1/Nrf2 signaling pathway in Wistar rats. <italic toggle="yes">Iran. J. Basic. Med. Sci.</italic><bold>25</bold> (12), 1522&#8211;1527 (2022).<pub-id pub-id-type="pmid">36544526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22038/IJBMS.2022.66823.14656</pub-id><pub-id pub-id-type="pmcid">PMC9742561</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chomczynski</surname><given-names>P</given-names></name></person-group><article-title>Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-choroform extraction</article-title><source>Anal. Biochem.</source><year>1987</year><volume>162</volume><fpage>156</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">2440339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/abio.1987.9999</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chomczynski, P. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-choroform extraction. <italic toggle="yes">Anal. Biochem.</italic><bold>162</bold>, 156&#8211;159 (1987).<pub-id pub-id-type="pmid">2440339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/abio.1987.9999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Mostafa, R. E. &amp; Abdel-Rahman, R. F. <italic toggle="yes">Ezetimibe alleviates acetic acid-induced ulcerative colitis in rats: targeting the Akt/NF-&#954;B/STAT3/CXCL10 signaling axis</italic>. <italic toggle="yes">J. Pharm. Pharmacol.</italic>, : p. rgad013. (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jpp/rgad013</pub-id><pub-id pub-id-type="pmid">36892981</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Carleton, H. M., Drury, R. A. B. &amp; Wallington, E. A. <italic toggle="yes">Carleton&#8217;s histological technique</italic> (Oxford University Press, 1980).</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#350;ener</surname><given-names>G</given-names></name><etal/></person-group><article-title>Resveratrol alleviates Bleomycin-induced lung injury in rats</article-title><source>Pulm. Pharmacol. Ther.</source><year>2007</year><volume>20</volume><issue>6</issue><fpage>642</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">17035056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pupt.2006.07.003</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">&#350;ener, G. et al. Resveratrol alleviates Bleomycin-induced lung injury in rats. <italic toggle="yes">Pulm. Pharmacol. Ther.</italic><bold>20</bold> (6), 642&#8211;649 (2007).<pub-id pub-id-type="pmid">17035056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pupt.2006.07.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protective roles of polysaccharides from ganoderma lucidum on Bleomycin-induced pulmonary fibrosis in rats</article-title><source>Int. J. Biol. Macromol.</source><year>2016</year><volume>92</volume><fpage>278</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">27381587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2016.07.005</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Chen, J. et al. Protective roles of polysaccharides from ganoderma lucidum on Bleomycin-induced pulmonary fibrosis in rats. <italic toggle="yes">Int. J. Biol. Macromol.</italic><bold>92</bold>, 278&#8211;281 (2016).<pub-id pub-id-type="pmid">27381587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2016.07.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Ekin, S. et al. <italic toggle="yes">Theophylline attenuates Bleomycin-induced oxidative stress in rats: the role of IL-6, NF-&#954;B, and antioxidant enzymes</italic>. <italic toggle="yes">Brazilian J. Pharm. Sci.</italic>, 58. (2022).</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Early and late changes of MMP-2 and MMP-9 in Bleomycin-induced pulmonary fibrosis</article-title><source>Yonsei Med. J.</source><year>2009</year><volume>50</volume><issue>1</issue><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">19259351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3349/ymj.2009.50.1.68</pub-id><pub-id pub-id-type="pmcid">PMC2649867</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Kim, J. Y. et al. Early and late changes of MMP-2 and MMP-9 in Bleomycin-induced pulmonary fibrosis. <italic toggle="yes">Yonsei Med. J.</italic><bold>50</bold> (1), 68&#8211;77 (2009).<pub-id pub-id-type="pmid">19259351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3349/ymj.2009.50.1.68</pub-id><pub-id pub-id-type="pmcid">PMC2649867</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salama</surname><given-names>AA</given-names></name><name name-style="western"><surname>Mostafa</surname><given-names>RE</given-names></name><name name-style="western"><surname>Elgohary</surname><given-names>R</given-names></name></person-group><article-title>Effect of L-carnitine on potassium dichromate-induced nephrotoxicity in rats: modulation of PI3K/AKT signaling pathway</article-title><source>Res. Pharm. Sci.</source><year>2022</year><volume>17</volume><issue>2</issue><fpage>153</fpage><pub-id pub-id-type="pmid">35280839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1735-5362.335174</pub-id><pub-id pub-id-type="pmcid">PMC8860102</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Salama, A. A., Mostafa, R. E. &amp; Elgohary, R. Effect of L-carnitine on potassium dichromate-induced nephrotoxicity in rats: modulation of PI3K/AKT signaling pathway. <italic toggle="yes">Res. Pharm. Sci.</italic><bold>17</bold> (2), 153 (2022).<pub-id pub-id-type="pmid">35280839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1735-5362.335174</pub-id><pub-id pub-id-type="pmcid">PMC8860102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Dexamethasone combined with Berberine is an effective therapy for Bleomycin&#8211;induced pulmonary fibrosis in rats</article-title><source>Experimental Therapeutic Med.</source><year>2019</year><volume>18</volume><issue>4</issue><fpage>2385</fpage><lpage>2392</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2019.7861</pub-id><pub-id pub-id-type="pmcid">PMC6755270</pub-id><pub-id pub-id-type="pmid">31555349</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Li, L. et al. Dexamethasone combined with Berberine is an effective therapy for Bleomycin&#8211;induced pulmonary fibrosis in rats. <italic toggle="yes">Experimental Therapeutic Med.</italic><bold>18</bold> (4), 2385&#8211;2392 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2019.7861</pub-id><pub-id pub-id-type="pmcid">PMC6755270</pub-id><pub-id pub-id-type="pmid">31555349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bormann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice</article-title><source>Respir. Res.</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">35804363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12931-022-02105-7</pub-id><pub-id pub-id-type="pmcid">PMC9270768</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Bormann, T. et al. Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice. <italic toggle="yes">Respir. Res.</italic><bold>23</bold> (1), 1&#8211;12 (2022).<pub-id pub-id-type="pmid">35804363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12931-022-02105-7</pub-id><pub-id pub-id-type="pmcid">PMC9270768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>N</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>RA</given-names></name></person-group><article-title>Biochemical and biological attributes of matrix metalloproteinases</article-title><source>Prog. Mol. Biol. Transl. Sci.</source><year>2017</year><volume>147</volume><fpage>1</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">28413025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2017.02.005</pub-id><pub-id pub-id-type="pmcid">PMC5430303</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Cui, N., Hu, M. &amp; Khalil, R. A. Biochemical and biological attributes of matrix metalloproteinases. <italic toggle="yes">Prog. Mol. Biol. Transl. Sci.</italic><bold>147</bold>, 1&#8211;73 (2017).<pub-id pub-id-type="pmid">28413025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2017.02.005</pub-id><pub-id pub-id-type="pmcid">PMC5430303</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oggionni</surname><given-names>T</given-names></name><etal/></person-group><article-title>Time course of matrix metalloproteases and tissue inhibitors in Bleomycin-induced pulmonary fibrosis</article-title><source>Eur. J. Histochem.</source><year>2006</year><volume>50</volume><issue>4</issue><fpage>317</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">17213041</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Oggionni, T. et al. Time course of matrix metalloproteases and tissue inhibitors in Bleomycin-induced pulmonary fibrosis. <italic toggle="yes">Eur. J. Histochem.</italic><bold>50</bold> (4), 317&#8211;326 (2006).<pub-id pub-id-type="pmid">17213041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Todd</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO registry cohort</article-title><source>BMC Pulm. Med.</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">32171287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12890-020-1103-4</pub-id><pub-id pub-id-type="pmcid">PMC7071646</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Todd, J. L. et al. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO registry cohort. <italic toggle="yes">BMC Pulm. Med.</italic><bold>20</bold> (1), 1&#8211;12 (2020).<pub-id pub-id-type="pmid">32171287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12890-020-1103-4</pub-id><pub-id pub-id-type="pmcid">PMC7071646</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios May be involved in lipopolysaccharide-induced acute lung injury</article-title><source>J. Int. Med. Res.</source><year>2020</year><volume>48</volume><issue>4</issue><fpage>0300060520919592</fpage><pub-id pub-id-type="pmid">32339071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300060520919592</pub-id><pub-id pub-id-type="pmcid">PMC7219017</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Chen, G. et al. Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios May be involved in lipopolysaccharide-induced acute lung injury. <italic toggle="yes">J. Int. Med. Res.</italic><bold>48</bold> (4), 0300060520919592 (2020).<pub-id pub-id-type="pmid">32339071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300060520919592</pub-id><pub-id pub-id-type="pmcid">PMC7219017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name><etal/></person-group><article-title>Rapamycin attenuates the paraquat-induced pulmonary fibrosis through activating Nrf2 pathway</article-title><source>J. Cell. Physiol.</source><year>2020</year><volume>235</volume><issue>2</issue><fpage>1759</fpage><lpage>1768</lpage><pub-id pub-id-type="pmid">31301076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29094</pub-id><pub-id pub-id-type="pmcid">PMC6899830</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Tai, W. et al. Rapamycin attenuates the paraquat-induced pulmonary fibrosis through activating Nrf2 pathway. <italic toggle="yes">J. Cell. Physiol.</italic><bold>235</bold> (2), 1759&#8211;1768 (2020).<pub-id pub-id-type="pmid">31301076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29094</pub-id><pub-id pub-id-type="pmcid">PMC6899830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inhibitory effects of total ginsenoside on Bleomycin-induced pulmonary fibrosis in mice</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>114</volume><fpage>108851</fpage><pub-id pub-id-type="pmid">30965234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2019.108851</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Yang, L. et al. Inhibitory effects of total ginsenoside on Bleomycin-induced pulmonary fibrosis in mice. <italic toggle="yes">Biomed. Pharmacother.</italic><bold>114</bold>, 108851 (2019).<pub-id pub-id-type="pmid">30965234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2019.108851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Protective effect of Rutin against bleomycin induced lung fibrosis: involvement of TGF-&#946;1/&#945;&#8208;SMA/Col I and III pathway</article-title><source>Biofactors</source><year>2020</year><volume>46</volume><issue>4</issue><fpage>637</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">32233122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/biof.1629</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Bai, L. et al. Protective effect of Rutin against bleomycin induced lung fibrosis: involvement of TGF-&#946;1/&#945;&#8208;SMA/Col I and III pathway. <italic toggle="yes">Biofactors</italic><bold>46</bold> (4), 637&#8211;644 (2020).<pub-id pub-id-type="pmid">32233122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/biof.1629</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grzegorzewska</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Dimethyl fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>41605</fpage><pub-id pub-id-type="pmid">28150703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep41605</pub-id><pub-id pub-id-type="pmcid">PMC5288696</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Grzegorzewska, A. P. et al. Dimethyl fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. <italic toggle="yes">Sci. Rep.</italic><bold>7</bold> (1), 41605 (2017).<pub-id pub-id-type="pmid">28150703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep41605</pub-id><pub-id pub-id-type="pmcid">PMC5288696</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Fang, L. et al. <italic toggle="yes">Osthole attenuates Bleomycin-induced pulmonary fibrosis by modulating NADPH oxidase 4-derived oxidative stress in mice.</italic> Oxidative Medicine and Cellular Longevity, 2021. (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/3309944</pub-id><pub-id pub-id-type="pmcid">PMC8437590</pub-id><pub-id pub-id-type="pmid">34527170</pub-id><related-article related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC10791196"/></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehdizadeh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Plumbagin attenuates Bleomycin-induced lung fibrosis in mice</article-title><source>Allergy Asthma Clin. Immunol.</source><year>2022</year><volume>18</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">36271442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13223-022-00734-7</pub-id><pub-id pub-id-type="pmcid">PMC9585773</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Mehdizadeh, S. et al. Plumbagin attenuates Bleomycin-induced lung fibrosis in mice. <italic toggle="yes">Allergy Asthma Clin. Immunol.</italic><bold>18</bold> (1), 1&#8211;8 (2022).<pub-id pub-id-type="pmid">36271442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13223-022-00734-7</pub-id><pub-id pub-id-type="pmcid">PMC9585773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Amelioration of Bleomycin-induced pulmonary fibrosis via TGF-&#946;-induced Smad and non-Smad signaling pathways in galectin-9-deficient mice and fibroblast cells</article-title><source>J. Biomed. Sci.</source><year>2020</year><volume>27</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31937306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-020-0616-8</pub-id><pub-id pub-id-type="pmcid">PMC6961390</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Hsu, Y. A. et al. Amelioration of Bleomycin-induced pulmonary fibrosis via TGF-&#946;-induced Smad and non-Smad signaling pathways in galectin-9-deficient mice and fibroblast cells. <italic toggle="yes">J. Biomed. Sci.</italic><bold>27</bold> (1), 1&#8211;9 (2020).<pub-id pub-id-type="pmid">31937306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-020-0616-8</pub-id><pub-id pub-id-type="pmcid">PMC6961390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Activation of PERK in ET-1&#8208;and thrombin&#8208;induced pulmonary fibroblast differentiation: inhibitory effects of Curcumin</article-title><source>J. Cell. Physiol.</source><year>2019</year><volume>234</volume><issue>9</issue><fpage>15977</fpage><lpage>15988</lpage><pub-id pub-id-type="pmid">30825198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.28256</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Chen, Y. C. et al. Activation of PERK in ET-1&#8208;and thrombin&#8208;induced pulmonary fibroblast differentiation: inhibitory effects of Curcumin. <italic toggle="yes">J. Cell. Physiol.</italic><bold>234</bold> (9), 15977&#8211;15988 (2019).<pub-id pub-id-type="pmid">30825198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.28256</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>CH</given-names></name><etal/></person-group><article-title>MPT0E028, a novel pan-HDAC inhibitor, prevents pulmonary fibrosis through Inhibition of TGF-&#946;-induced CTGF expression in human lung fibroblasts: involvement of MKP-1 activation</article-title><source>Eur. J. Pharmacol.</source><year>2024</year><volume>977</volume><fpage>176711</fpage><pub-id pub-id-type="pmid">38839029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2024.176711</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Liu, C. H. et al. MPT0E028, a novel pan-HDAC inhibitor, prevents pulmonary fibrosis through Inhibition of TGF-&#946;-induced CTGF expression in human lung fibroblasts: involvement of MKP-1 activation. <italic toggle="yes">Eur. J. Pharmacol.</italic><bold>977</bold>, 176711 (2024).<pub-id pub-id-type="pmid">38839029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2024.176711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulito-Cueto</surname><given-names>V</given-names></name><etal/></person-group><article-title>Matrix metalloproteinases and their tissue inhibitors as upcoming biomarker signatures of connective tissue diseases-related interstitial lung disease: towards an earlier and accurate diagnosis</article-title><source>Mol. Med.</source><year>2025</year><volume>31</volume><issue>1</issue><fpage>70</fpage><pub-id pub-id-type="pmid">39979794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10020-025-01128-2</pub-id><pub-id pub-id-type="pmcid">PMC11844142</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Pulito-Cueto, V. et al. Matrix metalloproteinases and their tissue inhibitors as upcoming biomarker signatures of connective tissue diseases-related interstitial lung disease: towards an earlier and accurate diagnosis. <italic toggle="yes">Mol. Med.</italic><bold>31</bold> (1), 70 (2025).<pub-id pub-id-type="pmid">39979794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10020-025-01128-2</pub-id><pub-id pub-id-type="pmcid">PMC11844142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Echinacea polysaccharide alleviates LPS-induced lung injury via inhibiting inflammation, apoptosis and activation of the TLR4/NF-&#954;B signal pathway</article-title><source>Int. Immunopharmacol.</source><year>2020</year><volume>88</volume><fpage>106974</fpage><pub-id pub-id-type="pmid">33182056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106974</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Zhang, H. et al. Echinacea polysaccharide alleviates LPS-induced lung injury via inhibiting inflammation, apoptosis and activation of the TLR4/NF-&#954;B signal pathway. <italic toggle="yes">Int. Immunopharmacol.</italic><bold>88</bold>, 106974 (2020).<pub-id pub-id-type="pmid">33182056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Guo, J. et al. <italic toggle="yes">Echinacea Polyphenols Inhibit NLRP3-Dependent Pyroptosis, Apoptosis, and Necroptosis Via Suppressing NO Production during Lipopolysaccharide-Induced Acute Lung Injury</italic> (Journal of Agricultural and Food Chemistry, 2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jafc.2c08382</pub-id><pub-id pub-id-type="pmid">37154470</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ABDELAZIZ</surname><given-names>HO</given-names></name><etal/></person-group><article-title>The possible protective role of Echinacea and ginger and both of them on the lung of diabetic male rats: histological and immunohistochemical study</article-title><source>Egypt. J. Histol.</source><year>2022</year><volume>45</volume><issue>3</issue><fpage>703</fpage><lpage>719</lpage></element-citation><mixed-citation id="mc-CR47" publication-type="journal">ABDELAZIZ, H. O. et al. The possible protective role of Echinacea and ginger and both of them on the lung of diabetic male rats: histological and immunohistochemical study. <italic toggle="yes">Egypt. J. Histol.</italic><bold>45</bold> (3), 703&#8211;719 (2022).</mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>